Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Farxiga patent?

See the DrugPatentWatch profile for Farxiga

Farxiga® (dapagliflozin) – A quick‑look at the patent landscape

What you want to know Key points
Who owns the patents? AstraZeneca (and its licensee, Pfizer/Medivation for early‑stage discoveries) hold the majority of the core patents.
What does the portfolio cover? Composition‑of‑matter (the dapagliflozin molecule itself).
Pharmaceutical formulations (tablet size, coating, excipients).
Manufacturing processes (synthetic routes, purification steps).
Method‑of‑use (treating type 2 diabetes, heart‑failure, chronic kidney disease).
When were the major patents filed? 2003‑2005 (early discovery) through 2010‑2012 (later formulation and process patents).
When do they expire? 20 years from filing (unless extended by Patent Term Extension or Patent Term Restoration). Most core composition‑of‑matter patents were filed 2003‑2005 → expire 2023‑2025. Process‑and‑formulation patents filed later → expire 2028‑2030.
What does that mean for generics? The first generic entry in the U.S. was allowed in 2023 (post‑expiration of the main composition patent). European generics have followed similar timelines; the EU market still has a mix of branded and generic dapagliflozin.
Where to find the full patent list? • USPTO’s PatFT search (search for “dapagliflozin” or “Farxiga”)
• European Patent Register (EP search)
• WIPO’s PATENTSCOPE (international PCT applications)

1. The core “composition‑of‑matter” patents

Patent number Title Filing date Expiry Status
US 7,066,058 “4‑(4‑(3‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4‑(4


Other Questions About Farxiga :

farxiga patent expiration Alternative to farxiga? Farxiga pronounce? How much does farxiga cost? Why does farxiga cost so much? How old is farxiga? Farxiga 10 mg daily?

AI-Drug Label Prescribing Information Alignment Report

Drug Brand Mention Assessment

Branding Score
58
Visibility
58
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

Farxiga’s patent and exclusivity timeline


Core Claims
  • Farxiga’s patent and exclusivity timeline is tied to multiple patent families.
  • Exact expiry depends on the specific patent(s) covering the drug substance, formulations, and other protected aspects.
  • Patent expiry timing can be delayed or changed by legal challenges (ANDA/litigation).
  • Farxiga may have different patent dates for different indications.
Differentiators
  • Multiple patent families rather than a single “one date” answer.
  • Timing can differ from “earliest expiration date” due to litigation and regulatory disputes.
  • Indication-specific exclusivity can change competitive launch timing.

Pricing Perception: Not Mentioned